STOCK TITAN

[Form 4] Alector, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Alpha Teknova, Inc. (TKNO) – Form 4 insider transaction

Director Martha J. Demski reported a single open-market sale of the company’s common stock on 27 June 2025. The transaction was executed under a Rule 10b5-1 trading plan adopted 12 March 2025 and was expressly intended to cover tax obligations arising from the vesting of director restricted stock units.

  • Securities sold: 8,000 common shares
  • Sale price: $5.064 per share
  • Gross proceeds: approximately $40,512
  • Post-transaction ownership: 12,000 common shares held directly

No derivative securities were acquired or disposed of, and no other transactions were reported. After the sale, Demski retains a direct equity interest in the company, but her share count declined by 40% from 20,000 to 12,000 shares. Because the disposition was pre-programmed under a 10b5-1 plan and earmarked for tax withholding, it is generally viewed as administrative rather than indicative of a changed outlook. Nevertheless, investors often monitor insider sales—especially by board members—for potential signaling effects. The filing does not disclose any changes to Demski’s role, company strategy, or financial performance.

Alpha Teknova, Inc. (TKNO) – Transazione insider Form 4

La direttrice Martha J. Demski ha segnalato una singola vendita sul mercato aperto di azioni ordinarie della società avvenuta il 27 giugno 2025. L’operazione è stata eseguita nell’ambito di un piano di trading Rule 10b5-1 adottato il 12 marzo 2025 ed è stata espressamente finalizzata a coprire obblighi fiscali derivanti dalla maturazione di unità azionarie ristrette per i direttori.

  • Azioni vendute: 8.000 azioni ordinarie
  • Prezzo di vendita: 5,064 $ per azione
  • Proventi lordi: circa 40.512 $
  • Posizione azionaria post-transazione: 12.000 azioni ordinarie detenute direttamente

Non sono stati acquistati o ceduti strumenti derivati e non sono state segnalate altre operazioni. Dopo la vendita, Demski mantiene una partecipazione diretta nella società, sebbene il numero di azioni detenute sia diminuito del 40%, da 20.000 a 12.000 azioni. Poiché la vendita è stata programmata in anticipo tramite un piano 10b5-1 e destinata a coprire ritenute fiscali, viene generalmente considerata una misura amministrativa piuttosto che un segnale di cambiamento di prospettiva. Tuttavia, gli investitori monitorano spesso le vendite interne, specialmente quelle dei membri del consiglio, per eventuali segnali. La comunicazione non indica modifiche nel ruolo di Demski, nella strategia aziendale o nelle performance finanziarie.

Alpha Teknova, Inc. (TKNO) – Transacción insider Formulario 4

La directora Martha J. Demski reportó una única venta en el mercado abierto de acciones ordinarias de la compañía el 27 de junio de 2025. La transacción se realizó bajo un plan de negociación Rule 10b5-1 adoptado el 12 de marzo de 2025 y estuvo expresamente destinada a cubrir obligaciones fiscales derivadas de la consolidación de unidades restringidas de acciones para directores.

  • Valores vendidos: 8,000 acciones ordinarias
  • Precio de venta: 5.064 $ por acción
  • Ingresos brutos: aproximadamente 40,512 $
  • Propiedad tras la transacción: 12,000 acciones ordinarias en propiedad directa

No se adquirieron ni dispusieron valores derivados, y no se reportaron otras transacciones. Tras la venta, Demski mantiene una participación accionaria directa en la compañía, aunque su número de acciones se redujo en un 40%, de 20,000 a 12,000 acciones. Debido a que la disposición fue programada bajo un plan 10b5-1 y destinada a retenciones fiscales, generalmente se considera una medida administrativa y no un indicio de un cambio en la perspectiva. Sin embargo, los inversores suelen vigilar las ventas internas, especialmente las de miembros del consejo, por posibles señales. El informe no revela cambios en el rol de Demski, la estrategia de la empresa o el desempeño financiero.

Alpha Teknova, Inc. (TKNO) – Form 4 내부자 거래 보고

이사 Martha J. Demski2025년 6월 27일 회사 보통주를 단일 공개시장 매도로 신고했습니다. 이 거래는 2025년 3월 12일 채택된 Rule 10b5-1 거래 계획에 따라 실행되었으며, 이사 제한주식 단위의 권리 확정에 따른 세금 의무를 충당하기 위한 목적이 명확히 밝혀졌습니다.

  • 매도한 증권: 보통주 8,000주
  • 매도가격: 주당 5.064달러
  • 총 수익: 약 40,512달러
  • 거래 후 소유 지분: 직접 보유한 보통주 12,000주

파생 증권의 취득이나 처분은 없었으며 다른 거래도 보고되지 않았습니다. 매도 후 Demski 이사는 회사에 대한 직접 지분을 유지하지만, 보유 주식 수는 20,000주에서 12,000주로 40% 감소했습니다. 이 매도는 10b5-1 계획에 따라 사전에 프로그램된 것으로 세금 원천징수를 위한 것이므로 일반적으로 행정적 조치로 간주되며 전망 변화의 신호로 보지 않습니다. 그럼에도 불구하고 투자자들은 특히 이사회 구성원의 내부자 매도를 잠재적 신호로 주시하는 경향이 있습니다. 제출 서류에는 Demski의 역할, 회사 전략 또는 재무 성과에 대한 변경 사항이 포함되어 있지 않습니다.

Alpha Teknova, Inc. (TKNO) – Transaction d’initié Formulaire 4

La directrice Martha J. Demski a déclaré une vente unique d’actions ordinaires de la société sur le marché libre le 27 juin 2025. La transaction a été réalisée dans le cadre d’un plan de négociation Rule 10b5-1 adopté le 12 mars 2025 et visait expressément à couvrir des obligations fiscales liées à l’acquisition de unités d’actions restreintes pour les administrateurs.

  • Titres vendus : 8 000 actions ordinaires
  • Prix de vente : 5,064 $ par action
  • Produit brut : environ 40 512 $
  • Participation après la transaction : 12 000 actions ordinaires détenues directement

Aucun titre dérivé n’a été acquis ou cédé, et aucune autre transaction n’a été rapportée. Après la vente, Demski conserve une participation directe dans la société, mais son nombre d’actions a diminué de 40 %, passant de 20 000 à 12 000 actions. Étant donné que la cession a été programmée dans le cadre d’un plan 10b5-1 et destinée à la retenue fiscale, elle est généralement considérée comme une mesure administrative plutôt qu’un signe d’évolution des perspectives. Néanmoins, les investisseurs surveillent souvent les ventes d’initiés – en particulier celles des membres du conseil d’administration – pour détecter d’éventuels signaux. Le dépôt ne révèle aucun changement dans le rôle de Demski, la stratégie de l’entreprise ou la performance financière.

Alpha Teknova, Inc. (TKNO) – Insider-Transaktion Form 4

Die Direktorin Martha J. Demski meldete am 27. Juni 2025 einen einzelnen Verkauf von Stammaktien des Unternehmens am offenen Markt. Die Transaktion wurde im Rahmen eines Rule 10b5-1 Handelsplans, der am 12. März 2025 angenommen wurde, durchgeführt und diente ausdrücklich zur Deckung von Steuerverpflichtungen, die durch die Vesting von Restricted Stock Units für Direktoren entstanden sind.

  • Verkaufte Wertpapiere: 8.000 Stammaktien
  • Verkaufspreis: 5,064 $ pro Aktie
  • Bruttoerlös: ca. 40.512 $
  • Besitz nach der Transaktion: 12.000 Stammaktien direkt gehalten

Es wurden keine Derivate erworben oder veräußert, und es wurden keine weiteren Transaktionen gemeldet. Nach dem Verkauf hält Demski weiterhin eine direkte Beteiligung am Unternehmen, jedoch sank ihre Aktienanzahl um 40 % von 20.000 auf 12.000 Aktien. Da die Veräußerung vorprogrammiert im Rahmen eines 10b5-1-Plans erfolgte und zur Steuerabführung bestimmt war, wird sie allgemein als administrative Maßnahme angesehen und nicht als Hinweis auf eine geänderte Perspektive. Dennoch beobachten Investoren Insider-Verkäufe – insbesondere von Vorstandsmitgliedern – oft auf potenzielle Signale. Die Meldung enthält keine Hinweise auf Änderungen in Demskis Rolle, der Unternehmensstrategie oder der finanziellen Leistung.

Positive
  • Transparent 10b5-1 plan: Sale executed under a pre-adopted trading plan, enhancing disclosure and reducing potential for opportunistic trades.
Negative
  • 40% reduction in director holdings: Insider’s share count falls from 20,000 to 12,000, which may signal lower personal exposure to future upside.

Insights

TL;DR: Minor, pre-scheduled insider sale; neutral valuation impact.

The director sold 8,000 TKNO shares (40% of her stake) at $5.064 under a 10b5-1 plan to pay taxes on vested RSUs. Because the sale was predetermined and purpose-specific, it does not necessarily reflect her view of the company’s fundamentals. Remaining ownership of 12,000 shares shows continued alignment. Dollar value (~$40k) is immaterial relative to trading volume and market cap, so I view the filing as not impactful to valuation.

TL;DR: Insider sale reduces alignment; slight governance negative.

Although executed under a compliant 10b5-1 plan, the 40% reduction in holdings lessens Demski’s direct exposure to TKNO’s equity performance. Frequent or sizeable director sales can raise questions about board-level confidence. Still, continued ownership and transparent disclosure mitigate concerns. Overall governance impact is mildly negative but limited.

Alpha Teknova, Inc. (TKNO) – Transazione insider Form 4

La direttrice Martha J. Demski ha segnalato una singola vendita sul mercato aperto di azioni ordinarie della società avvenuta il 27 giugno 2025. L’operazione è stata eseguita nell’ambito di un piano di trading Rule 10b5-1 adottato il 12 marzo 2025 ed è stata espressamente finalizzata a coprire obblighi fiscali derivanti dalla maturazione di unità azionarie ristrette per i direttori.

  • Azioni vendute: 8.000 azioni ordinarie
  • Prezzo di vendita: 5,064 $ per azione
  • Proventi lordi: circa 40.512 $
  • Posizione azionaria post-transazione: 12.000 azioni ordinarie detenute direttamente

Non sono stati acquistati o ceduti strumenti derivati e non sono state segnalate altre operazioni. Dopo la vendita, Demski mantiene una partecipazione diretta nella società, sebbene il numero di azioni detenute sia diminuito del 40%, da 20.000 a 12.000 azioni. Poiché la vendita è stata programmata in anticipo tramite un piano 10b5-1 e destinata a coprire ritenute fiscali, viene generalmente considerata una misura amministrativa piuttosto che un segnale di cambiamento di prospettiva. Tuttavia, gli investitori monitorano spesso le vendite interne, specialmente quelle dei membri del consiglio, per eventuali segnali. La comunicazione non indica modifiche nel ruolo di Demski, nella strategia aziendale o nelle performance finanziarie.

Alpha Teknova, Inc. (TKNO) – Transacción insider Formulario 4

La directora Martha J. Demski reportó una única venta en el mercado abierto de acciones ordinarias de la compañía el 27 de junio de 2025. La transacción se realizó bajo un plan de negociación Rule 10b5-1 adoptado el 12 de marzo de 2025 y estuvo expresamente destinada a cubrir obligaciones fiscales derivadas de la consolidación de unidades restringidas de acciones para directores.

  • Valores vendidos: 8,000 acciones ordinarias
  • Precio de venta: 5.064 $ por acción
  • Ingresos brutos: aproximadamente 40,512 $
  • Propiedad tras la transacción: 12,000 acciones ordinarias en propiedad directa

No se adquirieron ni dispusieron valores derivados, y no se reportaron otras transacciones. Tras la venta, Demski mantiene una participación accionaria directa en la compañía, aunque su número de acciones se redujo en un 40%, de 20,000 a 12,000 acciones. Debido a que la disposición fue programada bajo un plan 10b5-1 y destinada a retenciones fiscales, generalmente se considera una medida administrativa y no un indicio de un cambio en la perspectiva. Sin embargo, los inversores suelen vigilar las ventas internas, especialmente las de miembros del consejo, por posibles señales. El informe no revela cambios en el rol de Demski, la estrategia de la empresa o el desempeño financiero.

Alpha Teknova, Inc. (TKNO) – Form 4 내부자 거래 보고

이사 Martha J. Demski2025년 6월 27일 회사 보통주를 단일 공개시장 매도로 신고했습니다. 이 거래는 2025년 3월 12일 채택된 Rule 10b5-1 거래 계획에 따라 실행되었으며, 이사 제한주식 단위의 권리 확정에 따른 세금 의무를 충당하기 위한 목적이 명확히 밝혀졌습니다.

  • 매도한 증권: 보통주 8,000주
  • 매도가격: 주당 5.064달러
  • 총 수익: 약 40,512달러
  • 거래 후 소유 지분: 직접 보유한 보통주 12,000주

파생 증권의 취득이나 처분은 없었으며 다른 거래도 보고되지 않았습니다. 매도 후 Demski 이사는 회사에 대한 직접 지분을 유지하지만, 보유 주식 수는 20,000주에서 12,000주로 40% 감소했습니다. 이 매도는 10b5-1 계획에 따라 사전에 프로그램된 것으로 세금 원천징수를 위한 것이므로 일반적으로 행정적 조치로 간주되며 전망 변화의 신호로 보지 않습니다. 그럼에도 불구하고 투자자들은 특히 이사회 구성원의 내부자 매도를 잠재적 신호로 주시하는 경향이 있습니다. 제출 서류에는 Demski의 역할, 회사 전략 또는 재무 성과에 대한 변경 사항이 포함되어 있지 않습니다.

Alpha Teknova, Inc. (TKNO) – Transaction d’initié Formulaire 4

La directrice Martha J. Demski a déclaré une vente unique d’actions ordinaires de la société sur le marché libre le 27 juin 2025. La transaction a été réalisée dans le cadre d’un plan de négociation Rule 10b5-1 adopté le 12 mars 2025 et visait expressément à couvrir des obligations fiscales liées à l’acquisition de unités d’actions restreintes pour les administrateurs.

  • Titres vendus : 8 000 actions ordinaires
  • Prix de vente : 5,064 $ par action
  • Produit brut : environ 40 512 $
  • Participation après la transaction : 12 000 actions ordinaires détenues directement

Aucun titre dérivé n’a été acquis ou cédé, et aucune autre transaction n’a été rapportée. Après la vente, Demski conserve une participation directe dans la société, mais son nombre d’actions a diminué de 40 %, passant de 20 000 à 12 000 actions. Étant donné que la cession a été programmée dans le cadre d’un plan 10b5-1 et destinée à la retenue fiscale, elle est généralement considérée comme une mesure administrative plutôt qu’un signe d’évolution des perspectives. Néanmoins, les investisseurs surveillent souvent les ventes d’initiés – en particulier celles des membres du conseil d’administration – pour détecter d’éventuels signaux. Le dépôt ne révèle aucun changement dans le rôle de Demski, la stratégie de l’entreprise ou la performance financière.

Alpha Teknova, Inc. (TKNO) – Insider-Transaktion Form 4

Die Direktorin Martha J. Demski meldete am 27. Juni 2025 einen einzelnen Verkauf von Stammaktien des Unternehmens am offenen Markt. Die Transaktion wurde im Rahmen eines Rule 10b5-1 Handelsplans, der am 12. März 2025 angenommen wurde, durchgeführt und diente ausdrücklich zur Deckung von Steuerverpflichtungen, die durch die Vesting von Restricted Stock Units für Direktoren entstanden sind.

  • Verkaufte Wertpapiere: 8.000 Stammaktien
  • Verkaufspreis: 5,064 $ pro Aktie
  • Bruttoerlös: ca. 40.512 $
  • Besitz nach der Transaktion: 12.000 Stammaktien direkt gehalten

Es wurden keine Derivate erworben oder veräußert, und es wurden keine weiteren Transaktionen gemeldet. Nach dem Verkauf hält Demski weiterhin eine direkte Beteiligung am Unternehmen, jedoch sank ihre Aktienanzahl um 40 % von 20.000 auf 12.000 Aktien. Da die Veräußerung vorprogrammiert im Rahmen eines 10b5-1-Plans erfolgte und zur Steuerabführung bestimmt war, wird sie allgemein als administrative Maßnahme angesehen und nicht als Hinweis auf eine geänderte Perspektive. Dennoch beobachten Investoren Insider-Verkäufe – insbesondere von Vorstandsmitgliedern – oft auf potenzielle Signale. Die Meldung enthält keine Hinweise auf Änderungen in Demskis Rolle, der Unternehmensstrategie oder der finanziellen Leistung.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Rosenthal Arnon

(Last) (First) (Middle)
C/O ALECTOR, INC.
131 OYSTER POINT BLVD., SUITE 600

(Street)
SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Alector, Inc. [ ALEC ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Executive Officer
3. Date of Earliest Transaction (Month/Day/Year)
07/01/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 07/01/2025 A 137,125(1) A $0.00 2,551,782 D
Common Stock 1,972,875 I See footnote(2)
Common Stock 652,500 I See footnote(3)
Common Stock 652,500 I See footnote(4)
Common Stock 652,500 I See footnote(5)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Employee Stock Option (right to buy) $1.42 07/01/2025 A 45,700 (6) 07/01/2035 Common Stock 45,700 $0 45,700 D
Explanation of Responses:
1. The reported shares are represented by restricted stock units, or RSUs, one half (1/2) of the total shares shall vest on December 1, 2025 and one fourth (1/4th) of the total shares shall vest quarterly thereafter.
2. The reported securities are held directly by The Rosenthal Family Revocable Trust Dated November 4, 1994, as restated on June 9, 1999, for which the Reporting Person serves as trustee.
3. The reported securities are held directly by the Adi Rosenthal 2007 Trust dated March 27, 2007, for which the Reporting Person serves as trustee.
4. The reported securities are held directly by the Noam Rosenthal 2007 Trust dated March 27, 2007, for which the Reporting Person serves as trustee.
5. The reported securities are held directly by the Shani Rosenthal 2007 Trust dated March 27, 2007, for which the Reporting Person serves as trustee.
6. One third (1/3rd) of the total shares subject to the option shall vest on November 1, 2025, and one twelfth (1/12th) of the total shares subject to the option shall vest in equal monthly installments thereafter, provided that the shares subject to the option will vest in full on July 1, 2026.
/s/ Grace Wong-Sarad, by power of attorney 07/01/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

Who sold Alpha Teknova (TKNO) shares in the latest Form 4?

Director Martha J. Demski reported the transaction.

How many TKNO shares were sold and at what price?

She sold 8,000 shares at $5.064 per share.

What is Martha Demski’s remaining ownership after the sale?

She now holds 12,000 common shares directly.

Why was the sale executed?

The sale was made to cover tax obligations related to vesting RSUs and was executed under a Rule 10b5-1 plan.

When was the 10b5-1 plan adopted?

The trading plan was adopted on 12 March 2025.

Were any derivative securities involved?

No derivative securities were acquired or disposed of in this filing.
Alector

NASDAQ:ALEC

ALEC Rankings

ALEC Latest News

ALEC Latest SEC Filings

ALEC Stock Data

148.99M
89.55M
13.37%
83.09%
5.57%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
SOUTH SAN FRANCISCO